Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. AEMD
AEMD logo

AEMD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Aethlon Medical Inc (AEMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
1.650
1 Day change
-2.31%
52 Week Range
36.000
Analysis Updated At
2026/03/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Aethlon Medical Inc (AEMD) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows weak financial performance, no positive catalysts, and bearish technical indicators. Additionally, there are no significant trading trends or influential figures supporting the stock, and no proprietary trading signals suggest a strong buy opportunity.

Technical Analysis

The stock is currently bearish with a regular market price drop of -4.92%. The MACD is slightly positive but contracting, indicating weakening momentum. The RSI is neutral at 23.425, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.77), with resistance levels far above the current price (R1: 2.06).

Positive Catalysts

  • NULL. No recent news, no significant trading trends, and no AI or SwingMax trading signals.

Neutral/Negative Catalysts

  • and a significant EPS drop (-75.62% YoY). The stock has a low probability of significant short-term gains (40% chance of 1.74% in the next day, 4.3% in the next week).

Financial Performance

In Q3 2026, revenue remained at 0 with no growth. Net income improved by 15.01% YoY but remains negative at -2018245. EPS dropped significantly by -75.62% YoY, and gross margin remains at 0. Overall, the financials indicate poor performance and lack of growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast AEMD stock price to rise
Analyst Rating
0
Wall Street analysts forecast AEMD stock price to rise
Buy
Hold
Sell
0
Current: 1.690
sliders
Low
0
Averages
0
High
0
0
Current: 1.690
sliders
Low
0
Averages
0
High
0
H.C. Wainwright
Neutral
initiated
$1.50
AI Analysis
2025-07-07
Reason
H.C. Wainwright
Price Target
$1.50
AI Analysis
2025-07-07
initiated
Neutral
Reason
H.C. Wainwright assumed coverage of Aethlon Medical with a Neutral rating and $1.50 price target. The company is focused on developing and commercializing Hemopurifier, a medical device designed to deplete cancer-promoting exosomes or extracellular vesicles, the analyst tells investors in a research note. The firm is encouraged by Hemopurifier's market potential, but sees no major catalysts in the next 12 months.

People Also Watch